Cited 0 times in

67 9

Pitfalls in Reimbursement Decisions for Oncology Drugs in South Korea: Need for Addressing the Ethical Dimensions in Technology Assessment

Authors
 Eun Cho ; Eun-Cheol Park ; Myoung Sheen Kang 
Citation
 Asian Pacific Journal of Cancer Prevention, Vol.14(6) : 3785~3792, 2013 
Journal Title
 Asian Pacific Journal of Cancer Prevention 
ISSN
 1513-7368 
Issue Date
2013
Abstract
This study aimed to discover to what extent ethical issues are considered in the reimbursement decision process based on health technology assessment (HTA) in Korea, especially for oncology medications. Public summary documents (PSDs) published by the Health Insurance Review and Assessment Service (HIRA) were analyzed for empirical and normative factors. For external comparison, PSDs presented by corresponding institutions of Australia and the United Kingdom were employed. Furthermore, the opinions of eight expert oncologists were obtained regarding the accountability of the evidence in PSDs. Among 7 oncology drugs, there were differences in the final decisions and empirical factors considered, such as selected comparators and interpretation of evidencebetween the PSDs from the three institutions. From an ethical viewpoint, the following matters were deficient in the HTA decision-making process for oncology drugs: clear and reasonable standards; identifying a nd evaluating ethical values; and public accountability for reasonableness about decisions and due process.
URI
http://ir.ymlib.yonsei.ac.kr/handle/22282913/87447
DOI
10.7314/APJCP.2013.14.6.3785
Appears in Collections:
1. 연구논문 > 1. College of Medicine > Dept. of Preventive Medicine
Yonsei Authors
사서에게 알리기
  feedback
Files in This Item:
T201302548.pdfDownload
Export
RIS (EndNote)
XLS (Excel)
XML

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse